High-flow Nasal Cannula therapy: A feasible treatment for vulnerable elderly COVID-19 patients in the wards

Autor: Rachida el Moussaoui, Charlotte van Noord, Gert T. Verhoeven, Rikje Ruiter, Jan G. den Hollander, Christiaan J. van den Bout, Job van Steenkiste, Marinus A. van den Dorpel, Dolf Weller, Michael C. van Herwerden
Přispěvatelé: Epidemiology
Rok vydání: 2021
Předmět:
ACE
Angiotensine Converting Enzyme

medicine.medical_treatment
030204 cardiovascular system & hematology
Critical Care and Intensive Care Medicine
medicine.disease_cause
High-flow Nasal Cannula
law.invention
Hypoxemia
FiO2
Fraction of inspired oxygen

0302 clinical medicine
law
eGFR
estimated Glomerular Filtration Rate

COVID-19
Coronavirus disease 2019

Frailty
HFNC
High-flow nasal cannula

ARDS
Acute Respiratory Distress Syndrome

Intensive care unit
Hospitals
LD
Lactate dehydrogenase

Tolerability
NIV
Noninvasive Ventilation

ASAT
Aspartate transaminase (ASAT)

CT
Computed tomography

medicine.symptom
Respiratory Insufficiency
Cardiology and Cardiovascular Medicine
SOFA
Sequential Organ Failure

Nasal cannula
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Article
03 medical and health sciences
ICU
Intensive Care Unit

medicine
Cannula
Humans
Survival rate
Aged
Retrospective Studies
Mechanical ventilation
Noninvasive Ventilation
ALAT
Allanine transaminase

SARS-CoV-2
business.industry
Oxygen Inhalation Therapy
COVID-19
COPD
Chronic Obstructive Pulmonary Disease

Retrospective cohort study
CK
Creatine kinase

SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus 2

030228 respiratory system
Respiratory failure
Emergency medicine
BMI
Body Mass Index

business
FFP-2
Filtering Facepiece Particles-2
Zdroj: Heart and Lung, 50(5), 654-659. Mosby Inc.
Heart & Lung
ISSN: 0147-9563
DOI: 10.1016/j.hrtlng.2021.04.008
Popis: Background: Invasive mechanical ventilation is the treatment of choice in COVID-19 patients when hypoxemia persists, despite maximum conventional oxygen administration. Some frail patients with severe hypoxemic respiratory failure are deemed not eligible for invasive mechanical ventilation. Objectives: To investigate whether High-flow nasal cannula (HFNC) in the wards could serve as a rescue therapy in these frail patients. Methods: This retrospective cohort study included frail COVID-19 patients admitted to the hospital between March 9th and May 1st 2020. HFNC therapy was started in the wards. The primary endpoint was the survival rate at hospital discharge. Results: Thirty-two patients with a median age of 79.0 years (74.5–83.0) and a Clinical Frailty Score of 4 out of 9 (3–6) were included. Only 6% reported HFNC tolerability issues. The overall survival rate was 25% at hospital discharge. Conclusions: This study suggests that, when preferred, HFNC in the wards could be a potential rescue therapy for respiratory failure in vulnerable COVID-19 patients.
Databáze: OpenAIRE